WeightWatchers, formally known as WW International, has emerged from Chapter 11 protection after eliminating roughly $1.15 billion of debt—about 70 % of its total liabilities—and retaining its New York listing. The restructuring follows intense competition from telehealth providers and the rapid adoption of GLP-1 weight-loss drugs that disrupted the company’s traditional subscription model. As it relaunches, the company appointed Dr. Kim Boyd as chief medical officer, filling a position that had been vacant for nearly a year. Boyd, a former One Medical and Calibrate executive, will oversee clinical strategy and product innovation as WeightWatchers seeks to pair its behavioral-coaching heritage with modern medical treatments. Central to that strategy is a program due later this year aimed at women in peri-, menopausal and post-menopausal phases. The offering will combine hormone-replacement therapy prescriptions with nutritional, behavioral and community support, and will sit alongside partnerships that already give members access to FDA-approved obesity drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Chief Executive Tara Comonte said the blend of clinical expertise, lifestyle coaching and community engagement is intended to position the revamped company as a “trusted authority” in a weight-management market increasingly crowded with quick-fix solutions. WeightWatchers’ shares climbed as much as 14 % in early Wall Street trading on the announcements.